International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(20), P. 11299 - 11299
Published: Oct. 21, 2024
Cancer
patients,
especially
long
cancer
survivors,
are
exposed
to
several
cardio-metabolic
diseases,
including
diabetes,
heart
failure,
and
atherosclerosis,
which
increase
their
risk
of
cardiovascular
mortality.
Therapy
with
glucagon-like
peptide
1
(GLP1)
receptor
agonists
demonstrated
beneficial
effects,
atherosclerosis
failure
prevention.
Cardiovascular
outcome
trials
(CVOTs)
suggest
that
GLP-1
RA
could
exert
cardiorenal
benefits
systemic
anti-inflammatory
effects
in
patients
type-2
diabetes
through
the
activation
cAMP
PI3K/AkT
pathways
inhibition
NLRP-3
MyD88.
In
this
narrative
review,
we
highlight
biochemical
properties
a
deep
analysis
clinical
preclinical
evidence
primary
prevention
cardiomyopathies.
The
overall
picture
review
encourages
study
as
potential
strategy
against
atherosclerosis.
Journal of the American College of Cardiology,
Journal Year:
2024,
Volume and Issue:
84(17), P. 1587 - 1602
Published: Aug. 30, 2024
Obesity
is
associated
with
adverse
cardiac
remodeling
and
a
key
driver
for
the
development
progression
of
heart
failure
(HF).
Once-weekly
semaglutide
(2.4
mg)
has
been
shown
to
improve
HF-related
symptoms
physical
limitations,
body
weight,
exercise
function
in
patients
obesity-related
preserved
ejection
fraction
(HFpEF),
but
effects
on
structure
this
population
remain
unknown.
Journal of the American College of Cardiology,
Journal Year:
2024,
Volume and Issue:
84(17), P. 1646 - 1662
Published: Aug. 30, 2024
Inflammation
is
thought
to
be
an
important
mechanism
for
the
development
and
progression
of
obesity-related
heart
failure
with
preserved
ejection
fraction
(HFpEF).
In
STEP-HFpEF
Program,
once-weekly
2.4
mg
semaglutide
improved
failure-related
symptoms,
physical
limitations,
exercise
function,
reduced
levels
C-reactive
protein
(CRP),
a
biomarker
inflammation,
body
weight
in
participants
HFpEF.
However,
neither
prevalence
nor
clinical
characteristics
patients
who
have
various
magnitudes
inflammation
context
HFpEF
been
well
described.
Furthermore,
whether
beneficial
effects
on
HF
efficacy
endpoints
Program
are
modified
by
baseline
has
not
fully
established.
Finally,
relationship
between
reduction
changes
CRP
across
defined.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(9), P. 2112 - 2112
Published: Sept. 16, 2024
Obesity
is
a
significant
predisposing
factor
for
heart
failure
with
preserved
ejection
fraction
(HFpEF).
Although
substantial
proportion
of
individuals
HFpEF
also
have
obesity,
those
obesity
are
under-represented
in
clinical
trials
failure.
In
turn,
current
guidelines
provided
limited
recommendations
the
medical
management
this
patient
population.
Both
and
diabetes
induce
pro-inflammatory
state
that
can
contribute
to
endothelial
dysfunction
coronary
microvascular
impairment,
finally
resulting
HFpEF.
Additionally,
leads
increased
epicardial
chest
wall
adiposity,
which
enhances
ventricular
interdependence.
This
condition
further
aggravated
by
plasma
blood
volume
expansion
excessive
vasoconstriction,
ultimately
worsening
Despite
well-documented
benefits
GLP-1
receptor
agonists
subjects
diabetes,
or
both,
their
role
obesity-related
remains
unclear.
light
recently
published
literature,
review
aims
investigate
potential
mechanisms
synthesize
available
evidence
regarding
patients
Journal of the American College of Cardiology,
Journal Year:
2024,
Volume and Issue:
84(17), P. 1603 - 1614
Published: Aug. 30, 2024
Obesity
is
a
key
factor
in
the
development
and
progression
of
both
heart
failure
with
preserved
ejection
fraction
(HFpEF)
atrial
fibrillation
(AF).
In
STEP-HFpEF
Program
(comprising
[Research
Study
to
Investigate
How
Well
Semaglutide
Works
People
Living
With
Heart
Failure
Obesity]
DM
Look
at
Failure,
Type
2
Diabetes]
trials),
once-weekly
semaglutide
2.4
mg
improved
HF-related
symptoms,
physical
limitations,
exercise
function
reduced
body
weight
patients
obesity-related
HFpEF.
Whether
effects
this
patient
group
differ
participants
without
AF
(and
across
various
types)
has
not
been
fully
examined.
ESC Heart Failure,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 23, 2025
Abstract
Heart
failure
with
preserved
ejection
fraction
(HFpEF)
is
defined
by
heart
(HF)
a
left
ventricular
(LVEF)
of
at
least
50%.
HFpEF
has
complex
and
heterogeneous
pathophysiology
multiple
co‐morbidities
contributing
to
its
presentation.
Establishing
the
diagnosis
can
be
challenging.
Two
algorithms,
‘Heavy,
2
or
more
Hypertensive
drugs,
atrial
Fibrillation,
Pulmonary
hypertension,
Elderly
age
>60,
elevated
Filling
pressures’
(H
FPEF)
‘Heart
Failure
Association
Pre‐test
assessment,
Echocardiography
natriuretic
peptide,
Functional
testing,
Final
aetiology’
(HFA‐PEFF),
help
determine
likelihood
in
individuals
symptoms
HF.
Phenotype
clusters
largely
total
number
types
may
delineate
groups
patients
different
management
needs.
It
important
recognize
alternative
diagnoses
mimics
such
as
infiltrative
cardiomyopathies,
coronary
artery
disease,
lung
anxiety,
depression,
anaemia,
severe
obesity,
physical
deconditioning,
among
others.
Treatment
sodium‐glucose
co‐transporter
inhibitors
(dapagliflozin
empagliflozin)
recommended
for
all
unless
contraindicated.
Future
research
should
consider
approaches
guide
initial
treatment
HFpEF,
including
phenotype
clustering
models
artificial
intelligence,
whether
LVEF
most
useful
distinguishing
feature
categorizing
Ongoing
clinical
trials
are
evaluating
novel
pharmacological
device‐based
address
pathophysiological
consequences
HFpEF.
Cardiovascular Diabetology,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Nov. 15, 2024
Abstract
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs)
have
a
reliable
hypoglycaemic
and
weight-loss
effect
that
can
intervene
in
obesity,
which
is
the
basis
of
type
2
diabetes
pathology.
GLP-1RA
therapy
has
shown
potential
benefits
reducing
risk
major
adverse
cardiovascular
events
improving
kidney
outcomes
patients
with
at
high
for
disease.
More
recent
evidence
expanding
their
to
heart
failure
preserved
ejection
fraction
clinically
important
renal
without
diabetes.
Some
sub-analyses
large
clinical
trials
suggest
sodium-glucose
cotransporter
inhibitor
combination
may
provide
more
significant
reductions
hospitalization
composite
than
each
alone.
Moreover,
addition
finerenone
this
could
potentially
stronger
cardiorenal
protective
benefits.
Further
studies
are
needed
assess
determine
suitable
patient
population
therapy.
Graphical
abstract
Suspected
impacts
GLP-1RAs,
SGLT2is,
oncardiovascular
outcomes.
CV,
cardiovascular;
GLP-1RA,
glucagon-like
agonist;
HFpEF,
fraction;
HFrEF,
reduced
MI,
myocardial
infarction;
SGLT2i,
inhibitor.
